These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6385266)

  • 41. Mitoxantrone: a replacement for doxorubicin?
    Conner CS
    Drug Intell Clin Pharm; 1984 Jun; 18(6):479-80. PubMed ID: 6734434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Phase II study of mitoxantrone in advanced breast cancer].
    Ogawa M; Kubo K; Tominaga T; Nomura Y; Ota K; Yoshida M; Taguchi T; Hoshino A
    Gan To Kagaku Ryoho; 1986 May; 13(5):1980-4. PubMed ID: 3707156
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
    Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
    Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Mitoxantrone in the primary treatment of metastasizing breast cancer].
    Lenzhofer R; Rainer H; Schuster R; Pirker P; Dudczak R; Dittrich C; Moser K
    Wien Klin Wochenschr; 1984 Apr; 96(9):319-26. PubMed ID: 6475082
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
    Faulds D; Balfour JA; Chrisp P; Langtry HD
    Drugs; 1991 Mar; 41(3):400-49. PubMed ID: 1711446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
    Büyükünal E; Derman U; Serdengecti S; Berkarda B
    Chemioterapia; 1987 Oct; 6(5):377-9. PubMed ID: 3322590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
    Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
    Am J Clin Oncol; 1983 Feb; 6(1):45-8. PubMed ID: 6837506
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Phase II study of mitoxantrone].
    Tada A; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Adachi K; Nakada H; Okada Y
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1649-54. PubMed ID: 6476838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical safety and tolerance of mitoxantrone (Novantrone).
    Crossley RJ
    Cancer Treat Rev; 1983 Dec; 10 Suppl B():29-36. PubMed ID: 6362875
    [No Abstract]   [Full Text] [Related]  

  • 50. Mitoxantrone.
    Nathanson L
    Cancer Treat Rev; 1984 Dec; 11(4):289-93. PubMed ID: 6534511
    [No Abstract]   [Full Text] [Related]  

  • 51. Biologic and biochemical effects of mitoxantrone.
    Durr FE
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):3-10. PubMed ID: 6484579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study.
    Llombart-Cussac A; Pivot X; Rhor-Alvarado A; Le Cesne A; Le Chevalier T; Tursz T; Spielmann M
    Oncology; 1998; 55(5):384-90. PubMed ID: 9732214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study.
    Levin M; Pandya KJ; Khandekar JD; Horton J; Glick JH; Bennett JM; Muggia FM; Falkson G
    Cancer Treat Rep; 1984 Dec; 68(12):1511-2. PubMed ID: 6509455
    [No Abstract]   [Full Text] [Related]  

  • 54. [Phase II study of mitoxantrone for acute leukemia].
    Oguma S; Tatsumi Y; Hirayama F; Tani Y; Kubota Y; Kanakura Y; Ueda T; Nakamura H; Shibata H; Masaoka T
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):497-501. PubMed ID: 6703723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study.
    Pratt CB; Vietti TJ; Etcubanas E; Sexauer C; Krance RA; Mahoney DH; Patterson RB
    Invest New Drugs; 1986; 4(1):43-8. PubMed ID: 3700039
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Kaneko Y; Maseki N; Kumai R; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1453-7. PubMed ID: 4015120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I investigation of ametantrone.
    Loesch DM; Von Hoff DD; Kuhn J; Coltman CA; Tio F; Chaudhuri TK; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1983 Nov; 67(11):987-91. PubMed ID: 6640557
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer.
    Heidemann E; Steinke B; Hartlapp J; Schumacher K; Possinger K; Kunz S; Neeser E; von Ingersleben G; Hossfeld D; Waldmann R
    Onkologie; 1990 Feb; 13(1):24-7. PubMed ID: 2186320
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
    Alberts DS; Balcerzak SP; Bonnet JD; Stephens RL
    Cancer Treat Rep; 1985 Nov; 69(11):1321-3. PubMed ID: 4092195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.